Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Omeros Corp (OMER)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 940,800
  • Shares Outstanding, K 48,000
  • Annual Sales, $ 41,620 K
  • Annual Income, $ -66,750 K
  • 36-Month Beta 3.56
  • Price/Sales 13.59
  • Price/Cash Flow N/A
  • Price/Book 101.93

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.04 +0.22%
on 01/16/18
22.45 -19.47%
on 01/03/18
-1.48 (-7.57%)
since 12/15/17
3-Month
12.45 +45.22%
on 11/02/17
22.45 -19.47%
on 01/03/18
-1.25 (-6.47%)
since 10/16/17
52-Week
8.71 +107.58%
on 01/24/17
27.09 -33.26%
on 06/22/17
+8.75 (+93.78%)
since 01/13/17

Most Recent Stories

More News
Omeros Inks Agreement With FDA for OMS721 Phase III Trial

Omeros (OMER) inks an agreement with the FDA on Omeros' protocol for a phase III study to evaluate its lead pipeline candidate, OMS721, for treatment of patients with IgA nephropathy.

SCMP : 18.05 (unch)
ACRX : 2.08 (-3.49%)
OMER : 18.08 (-7.76%)
ALXN : 124.48 (+1.44%)
Omeros Corporation Reaches Agreement with FDA on OMS721 Phase 3 Trial Protocol for IgA Nephropathy

Omeros Corporation (Nasdaq: OMER) today announced that it has reached agreement with the US Food and Drug Administration (FDA) on Omeros' protocol for its Phase 3 clinical trial evaluating...

OMER : 18.08 (-7.76%)
SmarTrend Watching for Potential Rebound in Shares of Omeros Corp After 1.15% Loss

Omeros Corp (NYSE:OMER) traded in a range yesterday that spanned from a low of $19.06 to a high of $19.68. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $19.43...

OMER : 18.08 (-7.76%)
Technical Perspectives on Argos Therapeutics, Omeros, Regulus Therapeutics, and Rhythm Pharma

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on ARGS, OMER, RGLS, and RYTM which can be accessed for free by signing up to www.wallstequities.com/registration....

ARGS : 0.14 (-12.50%)
RYTM : 26.91 (-1.79%)
RGLS : 1.20 (-2.44%)
OMER : 18.08 (-7.76%)
Can Omeros (OMER) Run Higher on Strong Earnings Estimate Revisions?

Omeros (OMER) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision, along with decent short-term momentum.

OMER : 18.08 (-7.76%)
Omeros Corporation Announces FDA Approval of OMIDRIA(R) for Use in Pediatric Patients

Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market...

OMER : 18.08 (-7.76%)
Today's Research Reports on Stocks to Watch: Omeros Corporation and Ohr Pharmaceutical

NEW YORK, NY / ACCESSWIRE / December 4, 2017 / Shares of Ohr were skyrocketing on Friday after a positive publication from Cerebral Investing on why the firm is long on the stock. Shares of Omeros saw...

OHRP : 0.32 (-2.73%)
OMER : 18.08 (-7.76%)
New Research Coverage Highlights Wells Fargo, Omeros, Uranium Energy, Advisory Board, Twenty-First Century Fox, and SiteOne Landscape Supply -- Consolidated Revenues, Company Growth, and Expectations for 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Wells Fargo & Company (NYSE:WFC),...

SITE : 71.18 (-0.42%)
UEC : 1.63 (-5.23%)
ABCO : 53.83 (+0.09%)
WFC : 62.50 (-0.08%)
OMER : 18.08 (-7.76%)
FOX : 35.79 (-1.59%)
Today's Research Reports on Trending Tickers: Opko Health and Omeros Corporation

NEW YORK, NY / ACCESSWIRE / November 10, 2017 / U.S. markets record rally stalled on Thursday on concerns of a delay in President Trump's proposed tax plan. The Dow Jones Industrial Average declined 0.43...

OPK : 4.60 (-7.63%)
OMER : 18.08 (-7.76%)
Omeros Corporation Reports Third Quarter 2017 Financial Results

Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market...

OMER : 18.08 (-7.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM)...

See More

Key Turning Points

2nd Resistance Point 20.51
1st Resistance Point 19.29
Last Price 18.08
1st Support Level 17.45
2nd Support Level 16.83

See More

52-Week High 27.09
Fibonacci 61.8% 20.07
Last Price 18.08
Fibonacci 50% 17.90
Fibonacci 38.2% 15.73
52-Week Low 8.71

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.